|
Wednesday, 24 June 2009 12:30 Expert discussion (by invitation only)
Scientific Committee
Session I: Selected abstracts I
Chairs: Mario Dicato, MD and Eric Van Cutsem, MD, PhD
15:00 Welcome and introduction
Mario Dicato, MD and Eric Van Cutsem, MD, PhD 15:10 Presentation of selected abstracts Characterization of hereditary nonpolyposis colorectal cancer families (Lynch syndrome) from a single institution-based series of cases in Japan
T Yatsuoka, et al. Genomic profiling of KRAS/ BRAF/ PI3-Kinase mutations activating the epidermal growth factor receptor pathway in colorectal cancer
R Salazar, et al.
Molecular markers in colon cancer have a stage specific prognostic value. Results of the translational study on the PETACC 3 - EORTC 40993 -SAKK 60-00 trial
AD Roth, et al. BRAF V600E mutation and Amphiregulin (AR) immunohistochemical expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (mCRC) patients
C Cremolini, et al. Circulating endothelial cells (CECs) kinetic correlates with clinical response in metastatic colorectal cancer patients during first-line Bevacizumab-based treatment
Chatzileontiadou,et al.
Efficacy and safety of bevacizumab-based combination regimens in patients with metastatic colorectal cancer: Preliminary results from a randomised phase II study of bevacizumab + FOLFIRI vs. bevacizumab + XELIRI (FNCLCC ACCORD 13/0503 study)
Ml Ducreux, et al.
Session II: Cancer of the pancreas and bile ducts
Chairs: Manfred P. Lutz, MD and Karin Haustermans, MD, PhD
16:00 Does the knowledge on molecular markers have clinical implications in pancreatic cancer?
Margaret A. Tempero, MD 16:20 Diagnostic pitfalls in pancreatic cancer: Imaging and tissue
Pascal Hammel, MD 16:45 Presentation of selected abstracts Cationic liposomal paclitaxel in combination with gemcitabine in patients with unresectable pancreatic cancer: a randomized controlled Phase II trial
M Lutz, et al. A multicenter, randomized phase II trial of Gemcitabine and Oxaliplatin (GEMOX) alone or in combination with every-two-week Cetuximab in the first-line treatment of advanced biliary cancer
E Boucher, et al.
17:05 Debate: Is there a role for radiotherapy and chemoradiotherapy in pancreatic cancer?
Moderator: Jordan D. Berlin, MD
Pro: Karin Haustermans, MD, PhD
Con: Christophe Louvet, MD 17:30 Management of metastatic pancreatic cancer
Malcolm J. Moore, MD 17:50 A look into the future of metastatic pancreatic cancer: What is coming after gemcitabine?
Eileen O’Reilly, MD 18:05 Cases on pancreatic cancer
Jordan D. Berlin, MD
and Karin Haustermans, MD, PhD 18:20 Presentation of selected abstract Gemcitabine with or without cisplatin in patients (pts) with advanced or metastatic biliary tract cancer (ABC): Results of CA19.9 and quality of life analysis for the UK ABC-02 trial
H Wasan, et al.
18:30 Cholangiocarcinoma: Have we made progress in the surgical management?
Thomas Gruenberger, MD 18:50 Adjourn
Thursday, 25 June 2009
Session III: Meet the expert concurrent presentations
Level 1, Rooms 120-132 8:00 Biliary tract cancer
Michel Ducreux, MD, PhD Gastrointestinal lymphoma
Bertrand Coiffier, MD Liver metastases of unknown primary origin
Nicholas A. Pavlidis, MD, FACS Statistics for clinicians
Marc Buyse, ScD Video session: Resection of colorectal liver metastases
Graeme J. Poston, MD, FRCS New radiation techniques in GI cancer
Karin Haustermans, MD, PhD and Bruce D. Minsky, MD 8:50 Break
Session IV: Cancer of the liver
Chairs: Jordi Bruix, MD and Jordan D. Berlin, MD
9:00 Histopathology and molecular pathology
of liver cancer
Tania Roskams, MD, PhD 9:20 Presentation of selected abstracts A randomised phase II trial of a drug eluting bead in the treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization
K Malagari, et al.
Sunitinib malate in advanced hepatocellular carcinoma: preliminary results of a phase II study
A Iaculli, et al. 9:40 Treatment algorithm for HCC
Michel Ducreux, MD, PhD 10:00 Which new drugs and targets are on the horizon for HCC?
Jordi Bruix, MD 10:15 Keynote lecture 1: Statistics or endpoints
Marc Buyse, ScD 10:40 Break Group 1 poster viewing
(P0047-0059, P0091-0099, P0108-0117, P0200-0206, P0247-0264, P0294-0310)
Session V: Rare tumors: Neuroendocrine tumors and gastrointestinal stromal tumors (GIST)
Chairs: Michel Ducreux, MD, PhD and Eduardo Diaz-Rubio
11:10 The management of NET in 2009
Bertram Wiedenmann, MD 11:30 Presentation of selected abstracts Chromogranin A and neuron-specific enolase as biomarkers for everolimus efficacy in patients with advanced pancreatic neuroendocrine tumors after failure of chemotherapy
J Yao, et al. Phase III, Randomized, Double-Blind Trial of Sunitinib versus Placebo in patients with progressive, well-differentiated Pancreatic Islet Cell Tumours
E Raymond, et al. 11:50 ENETS lectures (European Neuroendocrine Tumor Society): How do we classify NET?
Guido Rindi, MD, PhD 12:10 The treatment of GIST tumors in 2009
Jean-Yves Blay, MD, PhD 12:30 Concurrent luncheon symposia
Session VI: Esophageal cancer
Chairs: Bruce D. Minsky, MD and Philippe Rougier, MD
14:30 How to detect dysplasia and early malignancy in Barrett’s esophagus
Ralf Kiesslich, MD, PhD 14:45 How to treat dysplasia and early malignancy in Barrett’s esophagus
Christian Ell, MD, PhD 15:00 Presentation of selected abstract Prediction of toxicity based on single nucleotide polymorphisms (SNP) in cisplatin (C) and radiation (RT) paths: Results from the Eastern Cooperative Oncology Group
HH Yoon, et al. 15:10 Esophageal cancer - surgery, chemoradiation, or both?
Bruce D. Minsky, MD 15:30 Travel Grant Award Ceremony 15:40 Break
Session VII: Gastric cancer
Chairs: Atsushi Ohtsu, MD, PhD
and Cornelis J.H. van de Velde, MD, PhD
16:10 Introduction: Should we eradicate Helicobacter pylori for gastric cancer prevention?
Peter Malfertheimer, MD 16:20 Optimal surgery for gastric cancer
Cornelis J.H. van de Velde, MD, PhD 16:40 Adjuvant or neoadjuvant treatment of resectable gastric cancer?
Arnaud D. Roth, MD 17:00 Is the neoadjuvant treatment strategy similar in GE junction adenocarcinoma and gastric cancer?
Philippe Rougier, MD 17:10 Case discussions
Arnaud D. Roth, MD and Philippe Rougier, MD 17:30 Presentation of selected abstracts First-line trastuzumab with chemotherapy in HER2-positive advanced or metastatic gastric cancer: Efficacy results from the ToGA trial
Y Bang, et al. Catumaxomab – a new treatment option for patients with malignant ascites
M Heiss, et al. 17:50 Have we made progress in the treatment of advanced gastric cancer?
Andres Cervantes, MD, PhD 18:10 Which new targets are on the horizon in gastric cancer?
Atsushi Ohtsu, MD, PhD 18:25 Adjourn 18:40 Satellite symposium
Friday, 26 June 2009
Session VIII: Meet the expert
concurrent sessions
Level 1, Rooms 120-132
Parallel with Session IX: Selected abstracts II 8:00 Anal Cancer
Cathy Eng, MD Biliary tract cancer
Michel Ducreux, MD, PhD Gastrointestinal lymphoma
Bertrand Coiffier, MD Liver metastases of unknown primary origin
Nicholas A. Pavlidis, MD, FACS ESSO Session: Video session on endoscopic techniques: New techniques for better imaging
of gastrointestinal cancer: Narrow band
imaging, chromoendoscopy
Ralf Kiesslich, MD, PhD Radiotherapy and SIRT for liver tumors
Laura A. Dawson, MD, FRCPC
Session IX: Selected abstracts II
Level 0, General Session Room
Parallel with Session VIII: Meet the expert session
Chairs: Alberto Sobrero, MD and Josep Tabernero, MD, PhD
8:00 Presentation of selected abstracts Bevacizumab (BV) in combination with FOLFOXIRI (irinotecan, oxaliplatin and infusional 5FU/LV) as first-line treatment of metastatic colorectal cancer (mCRC): A phase II trial by the GONO group
G Masi,et al. Management of epidermal-growth factor receptor inhibitor-related skin toxicity: A first-line, phase II study (20060314) of panitumumab with FOLFIRI in the treatment of metastatic colorectal cancer
K Meinolf, et al. Definition of oxaliplatin sensitivity in patients with advanced colorectal cancer previously treated with oxaliplatin-based therapy
A de Gramont, et al. Quality of life of patients with metastatic colorectal cancer receiving either XELOX or FOLFOX-6 regimen: A randomized phase III study
T Conroy, et al. Radiofrequency ablation combined with chemotherapy for unresectable CRC liver metastases: Interim results of a randomised phase II study (CLOCC) (EORTC-NCRI CCSG-ALM)
T Ruers, et al. First evaluation of phase III trial of TACE adopting Polyvinil-Alcohol Microspheres (PAM) Irinotecan (IRI) loaded vs FOLFIRI (CT) for non operable colorectal cancer (CRC) liver metastases
G Fiorentini, et al. 8:50 Break
Session X: Special nurses symposium – EONS symposium: Managing advanced gastrointestinal cancer
Level 1, Rooms 120-121
Parallel with Session XI: Colorectal cancer: Prevention, screening and nutrition
9:00 Metastatic pancreatic cancer: an overview
Malcolm J. Moore, MD 9:20 Palliative symptom management in metastatic pancreatic disease
Speaker invited 9:40 Palliative care services and supportive care
Speaker invited 10:00 Supportive care for patients with gastrointestinal cancers
Pernilla Lagergren, RN, PhD 10:20 The role of the nurse in the management of gastrointestinal cancer
Dawn Stiff, CNS 10:40 Questions 10:50 Break Group 2 Poster Viewing
(P0060-0090, P0100-0107, P0207-0246,
P0265-0293, P0038-0341, P0001-0041)
Session XI: Colorectal cancer: Prevention, screening and nutrition
Level 0, General Session Room
Parallel with Session X: Special nurses symposium –
EONS symposium
Chairs: Nadir Arber, MD, MSc, MHA
and Eduardo Diaz-Rubio, MD
9:00 Screening in the average population: How and when?
Nadir Arber, MD, MSc, MHA 9:20 Hereditary syndromes
Stefania Sciallero, MD 9:40 Virtual endoscopy: Is it ready to replace diagnostic colonoscopy?
Andrea Laghi, MD 10:00 New imaging techniques in the colon
Nadir Arber, MD, MSc, MHA 10:20 Keynote lecture 2: Angiogenesis
Peter Carmeliet, MD 10:50 Break
Session XII: Colorectal cancer: Liver metastases and peritoneal disease
Chairs: Bernard Nordlinger, MD and Rene Adam, MD, PhD
11:00 Presentation of selected abstracts ESSO Award winning abstract: “Staged” liver resection in synchronous and metachronous colorectal hepatic metastases; Differences in clinicopathological features and outcome
A. van der Pool, et al.
11:20 Oxford debate: This house believes that more and more surgical resections of metastases of CRC should be pursued
Rene Adam, MD, PhD
Eduardo Diaz-Rubio, MD
Bernard Nordlinger, MD
Alberto Sobrero, MD 11:50 What is the optimal chemotherapy for the neoadjuvant treatment of non-resectable liver metastases? Do we have to include biologicals in this setting?
Hans-Joachim Schmoll, MD, PhD 12:10 Is there a place for radiotherapy and SIRT
in liver metastases?
Francoise Mornex, MD, PhD 12:30 Debulking of peritoneal metastases and HIPEC
Andre D’Hoore, MD, PhD 13:00 Concurrent luncheon symposia 15:00 Keynote lecture 3: Chemoprevention of gastrointestinal cancer: Where are we in 2009?
Robert Bresalier, MD Friday, 26 June 2009 Session XIII: Multimodality therapy
for rectal cancer
Chairs: Bengt Glimelius, MD, PhD
and Robert Glynne-Jones, MD, FRCP 15:30 Is MRI mandatory in the staging of rectal cancer?
Gina Brown, MD 15:45 Presentation of selected abstract Preoperative fluorouracil (FU)-based chemoradiation +/- weekly oxaliplatin in locally advanced rectal cancer. Pathologic response analysis of the STAR (Studio Terapia Adiuvante Retto)-01 randomized phase III trial
C Aschele, et al. 15:55 Is sphincter preservation the goal?
Lars Pahlman, MD, PhD, FRCS 16:05 Break 16:35 What is the role of the pathologist in quality control of rectal cancer management?
Iris D. Nagtegaal, MD, PhD 16:50 Is local resection adequate for small tumors?
Emanuele Lezoche, MD, FACS 17:00 What is the standard neoadjuvant treatment in locally advanced rectal cancer? Outcome of ESMO/ESSO/ESTRO workshop
Vicenzo Valentini, MD 17:15 Does the chance of sphincter preservation increase after neoadjuvant chemoradiotherapy?
David Sebag-Montefiore, MD, FRCP, FRCR 17:25 What is the role of postoperative adjuvant chemotherapy?
Dirk Arnold, MD 17:40 How relevant is histological tumor regression grade after chemoradiotherapy?
Iris D. Nagtegaal, MD, PhD 17:50 Are moleculars markers useful for response prediction of chemoradiotherapy in rectal cancer?
Robert Glynne-Jones, MD, FRCP 18:00 Case discussions
Bengt Glimelius, MD, PhD
Session XIV: Poster discussion session
18:15 Poster discussion on colon cancer
Discussant: Josep Tabernero, MD, PhD Poster discussion on non-colorectal cancer
Discussant: Hans-Joachim Schmoll, MD, PhD
Posters to be discussed: PD0030-41 18:45 Adjourn 19:00 Satellite symposium
Saturday, 27 June 2009
Session XV: ESMO session: Focus on young medical oncologists – colorectal cancer
Chairs: Roberto Labianca, MD and
Serena Di Cosimo, MD 8:00 Oral presentation of selected abstract Is MGMT promoter methylation an early marker of tumour progression in colorectal cancer?
T Wenner, et al. 8:10 Award of selected abstract 8:15 How to select patients on the basis of molecular factors: The perspective of a YMO in the adjuvant setting
Fortunato Ciardiello, MD, PhD 8:35 How to select patients on the basis of molecular factors: The perspective of a YMO in advanced disease
Fotios Loupakis, MD 8:55 New “intelligent” drugs under evaluation: The case for PARP inhibitors
Alain J. Gelibter, MD 9:15 Break Group 3 poster viewing
(P0001-0046, P0118-0199, P0311-0337)
Session XVI: Metastatic colorectal cancer
Chairs: Eric Van Cutsem MD, PhD and Daniel G. Haller, MD
9:40 New paradigms of management of early lines of metastatic CRC
Axel Grothey, MD 10:00 Management after doublets and biologics fail (3rd line and beyond) in clinical practice
Tim Maughan, MD, FRCR, FRCP 10:20 Presentation of selected abstracts Utilizing predictive biomarkers to improve treatment outcomes in patients with metastatic colorectal cancer (mCRC): Results with cetuximab plus FOLFIRI in the CRYSTAL trial
P Rougier, et al. Duration of disease control (DDC) or time to failure of strategy (TFS) to evaluate a chemotherapy strategy in advanced colorectal cancer (ACC)
B Chibaudel, et al. 10:40 Optimal duration of treatment
Aimery De Gramont, MD 11:00 How to select patients for biological:
Angiogenesis inhibitors
James Cassidy, MD 11:15 EGFR inhibitors: KRAS and beyond
Fortunato Ciardiello, MD, PhD 11:30 Round table discussion: Management of colorectal cancer and selection of patients
Jim Cassidy, MD, Fortunato Ciardiello, MD, PhD and Aimery De Gramont, MD 12:00 New drugs on the horizon in metastatic
colorectal cancer
Josep Tabernero, MD, PhD 12:20 Keynote lecture 4: ESSO session: Quality assurance in colorectal cancer and GI cancer
Chair: Cornelis J.H. van de Velde, MD, PhD
Examples in Europe
Lars Pahlman, MD, PhD, FRCS and Fred Penninckx, MD, PhD 13:00 Concurrent luncheon symposia
Session XVII: Adjuvant therapy
for colon cancer
15:00 Introduction: What is high risk stage II
colon cancer?
Claus-Henning Kohne, MD, PhD 15:10 Presentation of selected abstracts Strength of association between 3 year (yr) Disease Free Survival (DFS) and Overall Survival (OS) differs between stage II/III Colon Cancer: Updated findings from 20,898 patient (pt) ACCENT dataset
A Grothey, et al. Validation of a robust prognostic genomic signature (ColoPrint) for stage II colon cancer patients in independent patient cohorts
R Salazar, et al. 15:30 Lessons from translational research from adjuvant trials in colon cancer
— the PETACC example
Sabine Tejpar, MD, PhD 15:45 Break 16:15 What is the role and the impact of
molecular markers on treatment decisions
in the adjuvant setting?
Heinz-Josef Lenz, MD 16:30 Adjuvant treatment of stage II and III colon cancer in 2009
Daniel G. Haller, MD
Session XVIII: Report on expert discussion
16:50 Biologics in colorectal cancer including
molecular markers
Mario Dicato, MD and Eric Van Cutsem, MD, PhD 17:10 Adjourn
|
